Drug intelligence / Profile preview

quavonlimab

Development stage: Phase 3
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Quavonlimab is an investigational human monoclonal antibody that targets cytotoxic T-lymphocyte antigen 4 (CTLA-4). It is being developed as an immunotherapy for various advanced cancers, including non-small cell lung cancer (NSCLC), malignant melanoma, liver cancer, and small-cell lung cancer. Quavonlimab acts as a CTLA-4 inhibitor, enhancing T lymphocyte activation and promoting anti-tumor immune responses. It has been studied both as monotherapy and in combination with pembrolizumab (an anti-PD-1 antibody) in multiple clinical trials. The drug is administered intravenously[1][2][3][4][5].

Brand names: quavonlimab
Other names: MK-1308MK1308MK 1308AK-107AK107AK 107

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on quavonlimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on quavonlimab.

Explore the full profile